Mycenax is a CMC-based biotech, and focuses on the development and manufacture of protein drug development, including new biological entities and biosimilars. Being as one of the Taiwan leading biopharmaceutical conglomerate, Mycenax is specialized in high quality and cost-competitive biological products development. With more than 17 years experiences of new biological entities and biosimilars drug development, Mycenax continues to provide CDMO services with innovative technology. Mycecax in-house pipelines include TuNEX, which already launched in Taiwan, and LusiNEX, a biosimilar of Tocilizumab that is being conducted for phase 1 trial in Australia. |